The microfluidics unit will be part of the newly formed U.S. subsidiary of Nuclera. Under the deal, E Ink will contribute intellectual property, equipment, and assistance from scientists and engineers and will be made the largest stakeholder in Nuclera.

Nuclera's desktop bioprinter, which is powered by microfluidic technology. Image courtesy of Nuclera.

The companies have been working together to create a bioprinter since 2018. E Ink's digital microfluidics has been combined with Nuclera's biopolymer synthesis technology to create lab-on-chip technology that allows users to digitally program bioprinting of proteins and genes on a desktop for next-day production.

The company expects to commercialize the product in 2022.

Researchers innovate drug discovery screening techniques
Researchers from around the globe gathered to discuss innovations in laboratory techniques such as phenotypic profiling and flow cytometry for drug discovery...

Digital microfluidic technique connects cells to their environment
A new digital microfluidic technique allows researchers to connect physical cell properties with the molecular makeup of individual cells. This new approach,...